Paris, December 7, 2009 - Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis S.A. (Alternext : ALCLS), today announced the launch of cGPS® NIH-3T3, its fist research kit that can be used to modify the NIH-3T3 cell line to study gene functions.
The NIH-3T3 cell line is commonly used in academic research laboratories as it is a good model for studying human gene functions as well. The new cGPS® kit developed by Cellectis bioresearch will allow scientists to perform targeted integration of a gene in NIH- 3T3 cells, a key step in the understanding of its function.
« This is the fifth product launched by Cellectis bioresearch this year and the first to address gene function studies, which is a huge market given the number of academic scientists that could have use of such a kit » said Luc Selig, VP Sales & Marketing for Cellectis bioresearch. « It is part of a portfolio that includes products for drug discovery and protein production in addition to those for the gene function studies. We plan to rollout a large line of new products to all three priority markets during 2010.
Cellectis bioresearch currently supplies two targeted integration product lines - cGPS® (cellular Genome Positioning System) and cGPS® Custom - both of which can be purchased via www.cellectis-bioresearch.com.
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of Cellectis S.A. (Alternext : ALCLS) in June 2008. It provides life sciences researchers with genome customization kits for rapid and efficient gene integration at a precise genomic position in a given cell type.
About Cellectis S.A.
Cellectis SA is a world leader in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in in vivo genome surgery addressing the therapeutic, agrofood, biomanufacturing and research sectors. Worldwide, Cellectis has entered into more than 50 agreements with major players in the pharma, biotech and agrobiotech industries and ahs over 20 collaborations with academic research groups. TO date, Cellectis has raised over €70 million in both equity operations and public financing and is listed on the NYSE Euronext Alternext market (ticker code : ALCLS). For more information on Cellectis, visit our website : www.cellectis.com
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in connection with its IPO and on which the French Autorité des marchés financiers (“AMF”) granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objective expressed by the forward-looking statements above.
